MAPK13 Inhibitor Compound 61 50 mg | ≥98% Cayman Chemical A p38δ MAPK inhibitor More Information Supplier Page × MAPK13 Inhibitor Compound 61
MAPK13 Inhibitor Compound 61 5 mg | ≥98% Cayman Chemical A p38δ MAPK inhibitor More Information Supplier Page × MAPK13 Inhibitor Compound 61
MAPK13 Inhibitor Compound 61 25 mg | ≥98% Cayman Chemical A p38δ MAPK inhibitor More Information Supplier Page × MAPK13 Inhibitor Compound 61
MAPK13 Inhibitor Compound 61 10 mg | ≥98% Cayman Chemical A p38δ MAPK inhibitor More Information Supplier Page × MAPK13 Inhibitor Compound 61
RGX-104 50 mg | ≥98% Cayman Chemical An LXRα and LXRβ agonist More Information Supplier Page × RGX-104
RGX-104 5 mg | ≥98% Cayman Chemical An LXRα and LXRβ agonist More Information Supplier Page × RGX-104
RGX-104 25 mg | ≥98% Cayman Chemical An LXRα and LXRβ agonist More Information Supplier Page × RGX-104
RGX-104 10 mg | ≥98% Cayman Chemical An LXRα and LXRβ agonist More Information Supplier Page × RGX-104
BTT3033 50 mg | ≥98% Cayman Chemical An integrin α2β1 inhibitor More Information Supplier Page × BTT3033
